Abstract
SUMMARYTreatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.
Publisher
Cambridge University Press (CUP)
Subject
Infectious Diseases,Animal Science and Zoology,Parasitology
Reference95 articles.
1. Update of DNDi's leishmaniasis R&D pipeline 2017. Available at https://www.dndi.org/wp-content/uploads/2017/05/DNDi_LeishmaniasisPipeline_2017.pdf
2. **LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine. Available at https://clinicaltrials.gov/ct2/show/NCT01751048
3. *London Declaration on Neglected Tropical Diseases. Available at http://unitingtocombatntds.org/sites/default/files/resource_file/london_declaration_on_ntds.pdf (Accessed 16 March 2015).
4. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases
5. A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献